Los Angeles Capital Management
ATNM icon

Los Angeles Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Los Angeles Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-233,247
Closed -$376K – 1335
2025
Q1 		$376K Buy
233,247
+19,297
+9% +$24.5K ﹤0.01% 827
2024
Q4 		$270K Buy
213,950
+42,770
+25% +$66.4K ﹤0.01% 967
2024
Q3 		$322K Buy
+171,180
New +$676K ﹤0.01% 986

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Los Angeles Capital Management's ATNM Position: Q2 2025 in Review

Los Angeles Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 233,247 shares — an estimated $376K sold.

Los Angeles Capital Management first reported a position in ATNM in Q3 2024 and held it in 3 quarters. The position peaked at $376K in Q1 2025. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

  • Los Angeles Capital Management reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Los Angeles Capital Management sold 233,247 Actinium Pharmaceuticals shares in Q2 2025, an estimated $376K.
  • Los Angeles Capital Management first reported a position in Actinium Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Los Angeles Capital Management's Actinium Pharmaceuticals position peaked at $376K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on Los Angeles Capital Management's 13F filing for Q2 2025, filed 7 Aug 2025.